Recent Transactions

Advising Bruc OPT Energy Partners (“BROP”), a renewable energy JV owned by OPTrust and Mr. Juan Béjar, on the sale of a 50% stake in Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development, to funds managed by Universities Superannuation Scheme (“USS”), the largest pension scheme by assets in the UK

Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm

Advised Credit Suisse Energy Infrastructure Partners (“CSEIP”), an investment boutique within the Asset Management business of Credit Suisse AG, on the acquisition of the 49% stake of 250MW Concentrated Solar Power (“CSP”) portfolio in Spain from ContourGlobal, an international owner and operator of contracted wholesale power generation businesses

Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners

Advised Oak Hill Advisors in the sale of Greenpark Aparcamientos, a leading off-street car park operator, to Parkia, a portfolio company of First State Investments

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.